Table 1

Characteristics of the total patient group and of patients developing liver dysfunction

Trial drugEnrolled patients (n)Positive PPD skin testSigns of latent TB on chest x rayPatients treated with INH (n)Patients with liver dysfunction (n)Age (years) and sex of patients with liver dysfunctionAST (ULN 45), ALT (ULN 46) (IU/l)Weeks of exposure to INH before liver dysfunction (n)Weeks before recovery after discontinuation of INH (n)
PPD, purified protein derivative; TB, tuberculosis; INH, isoniazid; AST, aspartate aminotransferase; ALT, alanine aminotransferase; MTX, methotrexate; SSZ, sulfasalazine; ULN, upper limit of normal.
MTX + infliximab (or placebo)54815248 – male50, 82148 (dose reduction MTX)
53 – male304, 12074
MTX + etanercept (or placebo)40000
SSZ + etanercept (or placebo)22303271 – female188, 330164
55 – male103, 197811
MTX + adalimumab (or placebo)80100
Total8811284